Curaleaf Challenges Aurora's Rejection of $5.00 Per Share Bid
Event summary
- Curaleaf's enhanced offer represents an 86% premium to Aurora's unaffected 30-day volume-weighted average share price, and a 217% premium on an ex-cash basis.
- Aurora's Board has denied Curaleaf diligence access while granting it to unnamed parties.
- Aurora's Adjusted EBITDA declined 63% over the last two quarters, attributing it to industry-wide headwinds.
- Curaleaf's implied transaction multiple for Aurora is 14.3x 2026 Adjusted EBITDA, higher than Curaleaf's multiple of 13.7x (IFRS).
- Aurora sold shares under its ATM program for as low as $2.60 per share in July 2026.
The big picture
Curaleaf's challenge to Aurora's rejection of its enhanced offer highlights a broader tension in the cannabis industry between strategic acquisitions and board-level resistance. The dispute underscores the importance of due diligence access and the potential for governance conflicts to derail value-maximizing deals. With Aurora's financial performance declining and Curaleaf offering a significant premium, the outcome will test the balance between shareholder interests and board discretion.
What we're watching
- Governance Dynamics
- Whether Aurora's Board can justify its rejection of Curaleaf's offer while granting diligence access to other parties.
- Execution Risk
- How Curaleaf's ability to substantiate its synergy estimates will impact the deal's progression.
- Market Reactions
- The pace at which Aurora's share price responds to the ongoing dispute and potential alternative bids.
